|
|
||||||||
Division of Cardiovascular and Thoracic Surgery, St. Lukes/Roosevelt Hospital, 1111 Amsterdam Ave, New York, NY 10025
(Email: dswistel@chpnet.org).
| The first 20% of the full text of this article appears below. |
For the last 10 years, cardiac resynchronization therapy (CRT) has emerged as an increasingly important therapeutic option in the management of heart failure, especially in light of stagnating numbers of available donor hearts and the ever enlarging number of individuals who would benefit from transplantation. Furthermore, proven improvement in clinical symptoms, hemodynamics, and quality of life have all been shown in nontransplant candidates. The authors in the preceding article [1] analyze the results of CRT on a large series of transplant candidates for an average period of 3 years. Their results are similar to our own [2], which show dramatic improvement in survival compared with historic controls, consisting of patients with similar New York Heart Association (NYHA) functional classification. The
Related Article
Ann. Thorac. Surg. 2009 87: 432-438.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |